Please ensure Javascript is enabled for purposes of website accessibility

FDA Grants a Priority Review To Gilead Sciences' Cancer Therapy

By Cory Renauer - Feb 10, 2020 at 2:18PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Gilead's next cell-based therapy could become a new lymphoma treatment option this summer.

Today, Gilead Sciences (GILD -0.47%) disclosed its next cell-based cancer therapy could become available this summer. The Food and Drug Administration recently granted a priority review to an application Gilead submitted a couple of months ago for KTE-X19 with an expected action date of Aug. 10, 2019.

Not exactly new

Gilead's potential new cancer therapy isn't exactly new. It's basically Yescarta with an improved manufacturing process that the company has aimed at a small segment of non-Hodgkin lymphoma patients. Yescarta and KTE-X19 are both CAR-T therapies made with cells harvested from patients that are trained to recognize cells with the CD19 antigen on their surface.

To get its hands on Yescarta and a handful of experimental CAR-T therapies in development, Gilead Sciences acquired Kite Pharma in 2017 for $11.9 billion.

Scientist reading a report.

Image source: Getty Images.

Since a new batch of Yescarta and KTE-X19 must be manufactured for every patient, many of whom need to begin a new treatment regimen immediately, improvements to the process can have a big effect. This appears to be the case with KTE-X19 and mantle cell lymphoma patients that have exhausted additional treatment options. During a study supporting Gilead's application, a single infusion of KTE-X19 helped 67% of patients achieve complete remission.

Getting crowded?

The FDA recently approved a Bruton's tyrosine kinase (BTK) inhibitor called Brukinsa from Beigene (BGNE -4.48%) for the treatment of mantle cell lymphoma patients who have relapsed at least once. Brukinsa itself is up against Imbruvica which has been in the second line position for mantle cell lymphoma patients since 2013.

Since just 6% of patients with non-Hodgkin lymphomas are diagnosed with the mantle cell variety, this space looks like it could get crowded fast. Sales of Gilead's new therapy will probably remain limited to a very small audience that has already exhausted all available treatment options.  

Cory Renauer owns shares of Gilead Sciences. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$66.02 (-0.47%) $0.31
BeiGene Stock Quote
BeiGene
BGNE
$179.82 (-4.48%) $-8.43

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
402%
 
S&P 500 Returns
129%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.